John Furey, Imvax executive chair December 2, 2025 06:30 AM EST Updated 03:20 PM FinancingStartupsManufacturing Im­vax shares Phase 2b da­ta for glioblas­toma treat­ment, plans to meet with FDA Kyle LaHucik Biotech Correspondent Im­vax, a biotech led by for­mer Spark Ther­a­peu­tics ex­ec­u­tives, says its glioblas­toma treat­ment was suc­cess­ful at keep­ing pa­tients alive about six months longer than stan­dard … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER